ARRAY BIOPHARMA INC
DelistedCIK 1100412fmd_19552NAZGC6RXBTFCN1FPYVHYVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2009 to Mar 31, 2019, 36 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 54 | 72 | 85 | 70 | 42 | 52 | 138 | 151 | 174 |
| Cost of revenue | 28 | 29 | 24 | 30 | 46 | 44 | 23 | 35 | 59 |
| Gross profit | 26 | 43 | 61 | 40 | (4) | 8 | 115 | 115 | 114 |
| Realized investment gains (losses) | – | – | – | – | – | 16 | 0 | 1 | 0 |
| Research and development | 72 | 63 | 57 | 59 | 50 | 54 | 161 | 178 | 186 |
| Total operating expenses | 118 | 109 | 96 | 109 | 118 | 130 | 220 | 253 | 304 |
| Operating income | (64) | (37) | (11) | (40) | (76) | 3 | (82) | (102) | (130) |
| Interest expense | 16 | 16 | 12 | 11 | 10 | 10 | 11 | 12 | 11 |
| Interest and investment income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Other non-operating income (expense) | – | – | – | (22) | (10) | 6 | (11) | (15) | (15) |
| Income before taxes | (78) | (56) | (24) | – | – | – | – | – | – |
| Income tax expense | – | – | 0 | – | – | – | 0 | 0 | 2 |
| Net income from continuing operations | – | – | (24) | – | – | – | – | – | – |
| Net income | (78) | (56) | (24) | (62) | (85) | 9 | (93) | (117) | (147) |